Matthew Suen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew Suen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jo-Anne Manski-Nankervis
Department of General Practice and Primary Care, The University of Melbourne, Melbourne, Victoria, Australia
3 shared publications - Barbara Hunter
Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia
2 shared publications - Caroline McBride
Department of General Practice and Primary Care, The University of Melbourne
2 shared publications - Natalie Lumsden
Department of General Practice and Primary Care, University of Melbourne, Melbourne, Australia
2 shared publications - Kaleswari Somasundaram
Department of General Practice and Primary Care, University of Melbourne, Parkville, Vic 3010, Australia
1 shared publication - Karin A. Thursky
Centre for Health Services Research in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1045
General Practitioner and Practice Manager Perspectives on an Integrated Antimicrobial Stewardship Program in Primary Care: A Qualitative Exploration
Background/Objectives: Antimicrobials are regularly prescribed in general practice, yet the infrastructure to support routine review of prescribing in this setting remains limited. Integrated antimicrobial stewardship (AMS) interventions combining automated auditing of routine prescribing data with an educational component are a promising approach to addressing this gap. This qualitative study aimed to explore general practitioner (GP) and practice manager (PM) perspectives on the acceptability, feasibility, and perceived effectiveness of such an intervention implemented across 31 general practices and 97 GPs in Victoria, Australia. It also explored implementation considerations relevant to future scaling of the intervention. This is one of the first studies of GP and PM perspectives on this type of integrated program. Methods: Semi-structured interviews were conducted with 17 GPs and 5 PMs and analyzed using both inductive and deductive thematic analysis. The Theoretical Domains Framework (TDF) informed interview guide development and deductive coding; themes were generated inductively and final themes mapped to the Capability, Opportunity, Motivation–Behavior (COM-B) model for presentation. Results: Four themes were identified: (1) trust, validity, and value of audit and feedback; (2) clinical judgement and patient factors in prescribing complexity; (3) social, organizational, and professional contexts of learning and behavior change; and (4) effort, usability, and workflow in engagement with the intervention. Conclusions: Participants valued AMS activities that supported reflective practice without undermining professional autonomy. Trust in the systems managing prescribing data was a precondition for engagement with the data itself. Engagement also depended on fit with existing workflows, individualized reporting, and contextualized feedback. The social conditions under which learning occurred, such as peer interaction, moderated discussion, and collaborative reflection, mattered as much as the technical components of a program.
- 22 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1045
Open AccessGeneral Practitioner and Practice Manager Perspectives on an Integrated Antimicrobial Stewardship Program in Primary Care: A Qualitative Exploration
Background/Objectives: Antimicrobials are regularly prescribed in general practice, yet the infrastructure to support routine review of prescribing in this setting remains limited. Integrated antimicrobial stewardship (AMS) interventions combining automated auditing of routine prescribing data with an educational component are a promising approach to addressing this gap. This qualitative study aimed to explore general practitioner (GP) and practice manager (PM) perspectives on the acceptability, feasibility, and perceived effectiveness of such an intervention implemented across 31 general practices and 97 GPs in Victoria, Australia. It also explored implementation considerations relevant to future scaling of the intervention. This is one of the first studies of GP and PM perspectives on this type of integrated program. Methods: Semi-structured interviews were conducted with 17 GPs and 5 PMs and analyzed using both inductive and deductive thematic analysis. The Theoretical Domains Framework (TDF) informed interview guide development and deductive coding; themes were generated inductively and final themes mapped to the Capability, Opportunity, Motivation–Behavior (COM-B) model for presentation. Results: Four themes were identified: (1) trust, validity, and value of audit and feedback; (2) clinical judgement and patient factors in prescribing complexity; (3) social, organizational, and professional contexts of learning and behavior change; and (4) effort, usability, and workflow in engagement with the intervention. Conclusions: Participants valued AMS activities that supported reflective practice without undermining professional autonomy. Trust in the systems managing prescribing data was a precondition for engagement with the data itself. Engagement also depended on fit with existing workflows, individualized reporting, and contextualized feedback. The social conditions under which learning occurred, such as peer interaction, moderated discussion, and collaborative reflection, mattered as much as the technical components of a program.
- Open Access
- 13 March 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e50737
Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study
Background: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. Objective: The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. Methods: Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. Results: In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. Conclusions: There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
- 13 March 2024
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 8 (1) , e50737
Open AccessImplementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study
Background: Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. Objective: The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. Methods: Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. Results: In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. Conclusions: There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
- Open Access
- 11 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Implementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study (Preprint)
BACKGROUND Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. OBJECTIVE The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. METHODS Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. RESULTS In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. CONCLUSIONS There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.
- 11 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessImplementing a Sodium-Glucose Cotransporter 2 Inhibitor Module With a Software Tool (Future Health Today): Qualitative Study (Preprint)
BACKGROUND Primary care plays a key role in the management of type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been demonstrated to reduce hospitalization and cardiac and renal complications. Tools that optimize management, including appropriate prescribing, are a priority for treating chronic diseases. Future Health Today (FHT) is software that facilitates clinical decision support and quality improvement. FHT applies algorithms to data stored in electronic medical records in general practice to identify patients who are at risk of a chronic disease or who have a chronic disease that may benefit from intensification of management. The platform continues to evolve because of rigorous evaluation, continuous improvement, and expansion of the conditions hosted on the platform. FHT currently displays recommendations for the identification and management of chronic kidney disease, cardiovascular disease, type 2 diabetes, and cancer risk. A new module will be introduced to FHT focusing on SGLT2 inhibitors in patients with type 2 diabetes who have chronic kidney diseases, cardiovascular diseases, or risk factors for cardiovascular disease. OBJECTIVE The study aims to explore the barriers and enablers to the implementation of an SGLT2 inhibitor module within the Future Health Today software. METHODS Clinic staff were recruited to participate in interviews on their experience in their use of a tool to improve prescribing behavior for SGLT2 inhibitors. Thematic analysis was guided by Clinical Performance Feedback Intervention Theory. RESULTS In total, 16 interviews were completed. Identified enablers of use included workflow alignment, clinical appropriateness, and active delivery of the module. Key barriers to use were competing priorities, staff engagement, and knowledge of the clinical topic. CONCLUSIONS There is a recognized benefit to the use of a clinical decision support tool to support type 2 diabetes management, but barriers were identified that impeded the usability and actionability of the module. Successful and effective implementation of this tool could support the optimization of patient management of type 2 diabetes in primary care.